IE50422B1 - Monoclonal-antibody-and method of preparing it composition containing it and its diagnostic and therapeutic uses - Google Patents

Monoclonal-antibody-and method of preparing it composition containing it and its diagnostic and therapeutic uses

Info

Publication number
IE50422B1
IE50422B1 IE840/80A IE84080A IE50422B1 IE 50422 B1 IE50422 B1 IE 50422B1 IE 840/80 A IE840/80 A IE 840/80A IE 84080 A IE84080 A IE 84080A IE 50422 B1 IE50422 B1 IE 50422B1
Authority
IE
Ireland
Prior art keywords
cells
monoclonal antibody
antibody
hybridoma
human
Prior art date
Application number
IE840/80A
Other languages
English (en)
Other versions
IE800840L (en
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21871750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IE50422(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of IE800840L publication Critical patent/IE800840L/xx
Publication of IE50422B1 publication Critical patent/IE50422B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G01N33/57505—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Hybrid Cells (AREA)
IE840/80A 1979-04-26 1980-04-25 Monoclonal-antibody-and method of preparing it composition containing it and its diagnostic and therapeutic uses IE50422B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/033,669 US4361549A (en) 1979-04-26 1979-04-26 Complement-fixing monoclonal antibody to human T cells, and methods of preparing same

Publications (2)

Publication Number Publication Date
IE800840L IE800840L (en) 1980-10-24
IE50422B1 true IE50422B1 (en) 1986-04-16

Family

ID=21871750

Family Applications (1)

Application Number Title Priority Date Filing Date
IE840/80A IE50422B1 (en) 1979-04-26 1980-04-25 Monoclonal-antibody-and method of preparing it composition containing it and its diagnostic and therapeutic uses

Country Status (22)

Country Link
US (1) US4361549A (cg-RX-API-DMAC10.html)
EP (1) EP0018795B2 (cg-RX-API-DMAC10.html)
JP (2) JPS55145617A (cg-RX-API-DMAC10.html)
AT (1) ATE14023T1 (cg-RX-API-DMAC10.html)
AU (1) AU544791B2 (cg-RX-API-DMAC10.html)
CA (1) CA1182406A (cg-RX-API-DMAC10.html)
DE (2) DE3070803D1 (cg-RX-API-DMAC10.html)
DK (1) DK154769C (cg-RX-API-DMAC10.html)
ES (1) ES8105152A1 (cg-RX-API-DMAC10.html)
FI (1) FI75183C (cg-RX-API-DMAC10.html)
HK (1) HK23886A (cg-RX-API-DMAC10.html)
IE (1) IE50422B1 (cg-RX-API-DMAC10.html)
IL (1) IL59917A (cg-RX-API-DMAC10.html)
MY (1) MY8600514A (cg-RX-API-DMAC10.html)
NL (1) NL930131I2 (cg-RX-API-DMAC10.html)
NO (1) NO159221C (cg-RX-API-DMAC10.html)
NZ (1) NZ193469A (cg-RX-API-DMAC10.html)
PH (1) PH16642A (cg-RX-API-DMAC10.html)
PT (1) PT71147B (cg-RX-API-DMAC10.html)
SG (1) SG6686G (cg-RX-API-DMAC10.html)
YU (1) YU48442B (cg-RX-API-DMAC10.html)
ZA (1) ZA802525B (cg-RX-API-DMAC10.html)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582797A (en) * 1980-09-25 1986-04-15 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
DE3105150A1 (de) * 1981-02-12 1982-08-19 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Herstellung von anti-t-lymphozyten-globulin.
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4657852A (en) * 1982-04-02 1987-04-14 The Board Of Trustees Of The Leland Stanford Junior University Method for B cell typing of total human lymphocyte sample
US4471056A (en) * 1982-04-02 1984-09-11 The Board Of Trustees Of The Leland Stanford Junior University Method for HLA-DR typing of total human lymphocyte sample
US4511662A (en) * 1982-06-18 1985-04-16 Bio-Rad Laboratories, Inc. Simultaneous assay for T and B lymphocyte populations and subpopulations
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4500637A (en) * 1982-07-19 1985-02-19 The United States Of America As Represented By The Department Of Health And Human Services Prevention of graft versus host disease following bone marrow transplantation
US4714613A (en) * 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4797475A (en) * 1983-05-20 1989-01-10 The Regents Of The University Of California Method and composition for isolating white cell elements
US4645738A (en) * 1983-09-30 1987-02-24 Memorial Sloan-Kettering Institute Cancer Center Method for differential diagnosis of T cell leukemias using monoclonal antibodies
US4468346A (en) * 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
US4661446A (en) * 1985-02-19 1987-04-28 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies and method of immunizing therewith
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4970299A (en) * 1986-07-03 1990-11-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies selective for prostate cancer
JPH03502280A (ja) * 1987-10-16 1991-05-30 バイオメディカル・システムズ・リミテツド Ｔ細胞系ｈｓｂ‐２およびｔ細胞性慢性リンパ性白血病（ｔ‐ｃｌｌ）細胞を加えて成長させた、正常ヒトｔおよびｂリンパ球ならびに単球と反応するマウス単クローン性抗体
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
JPH0291833U (cg-RX-API-DMAC10.html) * 1988-12-29 1990-07-20
JPH0277212U (cg-RX-API-DMAC10.html) * 1989-01-25 1990-06-13
EP0839536A1 (en) * 1989-10-27 1998-05-06 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
JPH0420550U (cg-RX-API-DMAC10.html) * 1990-06-11 1992-02-20
US5444155A (en) * 1991-09-10 1995-08-22 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US5250426A (en) * 1991-10-22 1993-10-05 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
AU692465B2 (en) * 1993-09-03 1998-06-11 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody that recognizes interstitial cell surface antigen
GB9513733D0 (en) * 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents
WO1997023237A1 (en) 1995-12-22 1997-07-03 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
CA2264548A1 (en) 1996-08-30 1998-03-05 Human Genome Sciences, Inc. Interleukin-19
CA2310805A1 (en) * 1997-11-24 1999-06-03 Johnson T. Wong Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US8557868B2 (en) * 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
US20060148665A1 (en) * 2000-11-08 2006-07-06 Bioconcept Laboratories Ophthalmic and contact lens solutions containing forms of vitamin b
US20060127496A1 (en) * 2000-11-08 2006-06-15 Bioconcept Laboratories L-histidine in ophthalmic solutions
US9492582B2 (en) * 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20070110782A1 (en) * 2000-11-08 2007-05-17 Fxs Ventures, Llc L-histidine in ophthalmic solutions
JP4084997B2 (ja) * 2000-11-08 2008-04-30 エフエックスエス・ベンチャーズ・エルエルシー 防腐剤増強剤として単純糖類を含有する改良眼科用およびコンタクトレンズ用溶液
WO2002062260A2 (en) * 2000-11-08 2002-08-15 Bio-Concept Laboratories Improved ophthalmic and contact lens solutions containing forms of vitamin b
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US20070104744A1 (en) * 2000-11-08 2007-05-10 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
US7939501B2 (en) * 2003-04-15 2011-05-10 Smith Francis X Ophthalmic and contact lens solutions containing peptides as preservative
JP4948174B2 (ja) 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
AU2004291107B2 (en) * 2003-11-14 2010-09-30 Brigham And Women's Hospital, Inc. Methods of modulating immunity
SG10201504917PA (en) * 2005-07-11 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
BRPI0713426A2 (pt) * 2006-06-14 2012-10-09 Macrogenics Inc métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
BRPI0721062A2 (pt) * 2006-12-21 2019-09-24 Macrogenics Inc métodos para prevenir ou retardar o início e para prevenir a progressão de diabete autoimune latente, métodos para tratamento de diabete autoimune latente em adultos e para tratar ou prevenir diabete de tipo 1 de início na idade adulta ou para melhorar seus sintomas em um paciente sofrendo do mesmo, e, método para prevenir ou retardar requisição de insulina em um paciente.
DK2907873T3 (en) 2009-07-17 2016-06-13 Bioatla Llc Simultaneously integrated selection and development of antibody / protein performance and their expression in production hosts
KR20130066626A (ko) 2010-04-29 2013-06-20 나스벡스 엘티디. 항ｃｄ3 면역 분자 요법을 사용하여 간염을 치료하는 방법 및 이를 위한 조성물
WO2012009026A2 (en) 2010-07-16 2012-01-19 Bioatla Llc Novel methods of protein evolution
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
WO2012092374A2 (en) 2010-12-31 2012-07-05 Short Jay M Express humanization of antibodies
CN105924519B (zh) 2010-12-31 2019-08-23 生物蛋白有限公司 全面单克隆抗体产生
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
DK2847231T3 (da) 2012-05-10 2019-10-14 Bioatla Llc Multispecifikke monoklonale antistoffer
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US11293929B2 (en) 2014-01-07 2022-04-05 Bioatla, Inc. Proteins targeting orthologs
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3988920A1 (en) 2014-04-16 2022-04-27 Juno Therapeutics GmbH Methods, kits and apparatus for expanding a population of cells
MA39867A (fr) 2014-04-23 2017-03-01 Juno Therapeutics Inc Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
HUE071048T2 (hu) 2014-11-17 2025-07-28 Regeneron Pharma Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával
TW202402802A (zh) 2015-01-23 2024-01-16 法商賽諾菲公司 特異性結合ｃｄ３及／或ｃｄ１２３之抗—ｃｄ３抗體，抗—ｃｄ１２３抗體及雙特異性抗體
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
JP7195141B2 (ja) 2015-10-22 2022-12-23 ジュノ セラピューティクス ゲーエムベーハー 形質導入のための方法、キット、作用物質および装置
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
WO2017134302A2 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Targeted therapeutic agents and uses thereof
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
EP3576765B1 (en) 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
BR112019022356A2 (pt) 2017-04-27 2020-05-26 Juno Therapeutics Gmbh Reagentes de partícula oligoméricos e métodos de uso dos mesmos
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
AU2019370705B2 (en) 2018-10-31 2026-01-22 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
ES2968737T3 (es) 2018-11-06 2024-05-13 Juno Therapeutics Inc Proceso para producir células T manipuladas genéticamente
US20220348660A1 (en) 2019-10-02 2022-11-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of adult t-cell leukemia/lymphoma
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
MX2022009830A (es) 2020-02-12 2022-10-28 Juno Therapeutics Inc Composiciones de celulas t que expresan receptores de antigenos quimericos dirigidos a bcma y metodos y usos de las mismas.
CN115768443A (zh) 2020-02-12 2023-03-07 朱诺治疗学股份有限公司 Cd19定向嵌合抗原受体t细胞组合物和方法及其用途
JP2023517611A (ja) 2020-03-10 2023-04-26 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー Ｉｌ－６／ｉｌ－６ｒ抗体の組成物及びその使用方法
EP4150057A2 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
US20230190804A1 (en) 2020-06-17 2023-06-22 Tiziana Life Sciences Plc Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
EP4188440A2 (en) 2020-07-30 2023-06-07 Tiziana Life Sciences PLC Cd-3 antibodies for the treatment of coronavirus
US20220332822A1 (en) 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
AU2022365121A1 (en) 2021-10-14 2024-04-18 The Brigham And Women's Hospital, Inc. Methods of suppressing microglial activation
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023147331A1 (en) 2022-01-26 2023-08-03 Mabswitch Inc. Bispecific molecule with tunable affinity to a targetted antigen
WO2023147510A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Chromatography arrays and related methods and kits
US20250152709A1 (en) 2022-02-01 2025-05-15 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
IL322815A (en) 2023-02-28 2025-10-01 Juno Therapeutics Inc Cell therapy for the treatment of systemic autoimmune diseases
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025049253A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Bridged cycle‑based inhibitors of dna‑dependent protein kinase and compositions and application in gene editing
WO2025049254A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049247A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. 5,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049250A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. 6,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025083196A1 (en) 2023-10-18 2025-04-24 Tq Therapeutics Gmbh A method of manufacturing a cellular therapy product and respective kits and devices
WO2025160395A1 (en) 2024-01-25 2025-07-31 Juno Therapeutics, Inc. Use of bridged cycle-based inhibitors of dna-dependent protein kinase in combination of dna polymerase theta inhibitor and compositions and application in gene editing
WO2025179188A1 (en) 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR956062A (cg-RX-API-DMAC10.html) * 1950-01-24
GB824492A (en) * 1955-10-07 1959-12-02 Frederick William Beinlich Process and apparatus for the generation of power
US3988895A (en) * 1974-01-11 1976-11-02 Itzhak Sheinbaum Power generation from hot brines
US3986362A (en) * 1975-06-13 1976-10-19 Petru Baciu Geothermal power plant with intermediate superheating and simultaneous generation of thermal and electrical energy
US4089175A (en) * 1975-06-23 1978-05-16 Occidental Petroleum Corporation Process and system for recovery of energy from geothermal brines and other water containing sources by direct contact with a working fluid below the critical pressure
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
BE875277A (fr) * 1979-04-02 1979-10-02 Jourdain Leon J Machine motrice
US4284412A (en) * 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses

Also Published As

Publication number Publication date
JPS6362520B2 (cg-RX-API-DMAC10.html) 1988-12-02
SG6686G (en) 1986-08-01
EP0018795A3 (en) 1981-01-07
PH16642A (en) 1983-12-06
AU544791B2 (en) 1985-06-13
EP0018795B2 (en) 1999-04-07
DE18795T1 (de) 1984-07-19
DK154769B (da) 1988-12-19
PT71147B (en) 1981-08-11
IL59917A0 (en) 1980-06-30
YU48442B (sh) 1998-07-10
EP0018795A2 (en) 1980-11-12
FI75183B (fi) 1988-01-29
NO159221C (no) 1988-12-07
DK180380A (da) 1980-10-27
FI801342A7 (fi) 1980-10-27
NZ193469A (en) 1984-07-06
NL930131I1 (nl) 1993-11-01
ATE14023T1 (de) 1985-07-15
IE800840L (en) 1980-10-24
DE3070803D1 (en) 1985-08-01
YU114680A (en) 1984-02-29
ES490944A0 (es) 1981-05-16
FI75183C (fi) 1988-05-09
MY8600514A (en) 1986-12-31
DK154769C (da) 1989-06-19
US4361549A (en) 1982-11-30
AU5775780A (en) 1980-10-30
IL59917A (en) 1983-12-30
NO159221B (no) 1988-08-29
HK23886A (en) 1986-04-11
JPH0198478A (ja) 1989-04-17
JPS55145617A (en) 1980-11-13
ES8105152A1 (es) 1981-05-16
EP0018795B1 (en) 1985-06-26
CA1182406A (en) 1985-02-12
PT71147A (en) 1980-05-01
NL930131I2 (nl) 1998-07-01
NO801214L (no) 1980-10-27
ZA802525B (en) 1981-12-30
JPH0159868B2 (cg-RX-API-DMAC10.html) 1989-12-20

Similar Documents

Publication Publication Date Title
EP0018795B2 (en) Monoclonal-antibody-producing hybrid cell line, antibody and method of preparing it, therapeutic composition containing it and its diagnostic and therapeutic uses
US4515893A (en) Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4657760A (en) Methods and compositions using monoclonal antibody to human T cells
US4658019A (en) Complement-fixing monoclonal antibody to human T cells
US4363799A (en) Monoclonal antibody to human T cells, and methods for preparing same
EP0018794B1 (en) Monoclonal antibody to human helper t cells, method of preparing it, hybrid cell line producing it, its diagnostic and therapeutic uses and diagnostic and therapeutic compositions comprising it
US4364935A (en) Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
EP0033578B1 (en) Hybrid cell line for producing monoclonal antibody to a human t cell antigen, antibody, and methods
US4364936A (en) Monoclonal antibody to a human monocyte antigen and methods of preparing same
EP0030450A2 (en) Hybrid cell line for producing complement-fixing, monoclonal antibody to human suppressor T cells, antibody, method of preparation of this antibody, diagnostic and therapeutic uses and pharmaceutical compositions comprising this antibody
EP0025722B2 (en) Monoclonal antibody to human cytotoxic and suppressor T cells, and method of preparing it
US4654210A (en) Methods and compositions using complement fixing monoclonal antibody to human T cells
NZ195648A (en) Hybridoma for producing monoclonal antibody to human thymocytes;antibody;therapeutic compositions and diagnostic methods
IE50672B1 (en) Hybrid cell line for producing monoclonal antibody to human thymocyte antigen,antibody,method of preparation of this antibody,diagnostic and therapeutic uses and pharmaceutical compositions comprising this antibody
US4658020A (en) Monoclonal antibody to human helper T cells
US4515895A (en) Hybrid cell line for producing monoclonal antibody to human helper T cells
US4652447A (en) Methods and compositions using monoclonal antibody to human helper T cells
US4515894A (en) Hybrid cell line for producing monoclonal antibody to human T cells
US4803262A (en) Hybrid cell line for producing monoclonal antibody to human cytotoxic and suppressor T cells, antibody, and methods
US4680383A (en) Monoclonal antibody to human T cells
US4637983A (en) Hybrid cell line for producing monoclonal antibody to human cytotoxic and suppressor T cells, antibody, and methods
US4959458A (en) Hybrid cell line for producing monoclonal antibody to a human monocyte antigen, antibody, and methods

Legal Events

Date Code Title Description
MK9A Patent expired